Results 141 to 150 of about 78,685 (264)

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Mapping the experiences of adult cancer patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: A scoping review protocol. [PDF]

PLoS One
Girleanu I, Brady AM, Boland V.
europepmc   +1 more source

Advances and perspectives in animal models of human hepatitis A virus

Animal Models and Experimental Medicine, EarlyView.
Following HAV infection, humans, non‐human primates, and Ifnar1−/− mice develop characteristic manifestations of hepatitis A, including fecal viral shedding, elevated serum ALT levels, and inflammatory cell infiltration in the liver. In contrast, HAV‐infected human liver chimeric mice exhibit fecal viral shedding but do not develop clinical features of
Jian Li, Pei‐Yu Jiang, Hui Zhao, Cheng‐Feng Qin   +3 more
wiley   +1 more source

Sialic acid <i>cis</i>-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. [PDF]

Oncoimmunology
van Eck van der Sluijs J, Valk AHC, van Houtum EJH, Kers-Rebel ED, Looman M, Hobo W, Marneth AE, Dolstra H, van den Boogaard L, Büll C, Cornelissen LAM, Adema GJ.   +11 more
europepmc   +1 more source

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma. [PDF]

JCO Clin Cancer Inform
Malek E, Betts B, Herr M, Davila M, Holtan S, Driscoll JJ, Yu H.   +6 more
europepmc   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action. [PDF]

Toxins (Basel)
Kalmantaeva OV, Marin MA, Ershova AA, Ryabko AK, Romanenko YO, Kombarova TI, Dyatlov IA, Firstova VV.   +7 more
europepmc   +1 more source

Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Advanced NanoBiomed Research, EarlyView.
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham, Karthikeya S. V. Gottimukkala, Daniel D. Lane, Katrina Poljakov, Patricia Lipson, Mark R. Enstrom, Alessandro Rizzi, Aude G. Chapuis, Jennifer E. Adair   +8 more
wiley   +1 more source

Editorial: Interdisciplinary innovations in CAR T-cell therapy for autoimmune and cancer treatment. [PDF]

Front Immunol
Zaravinos A, Unutmaz D, Radic M.
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source